Serum biomarkers and anti-flavivirus antibodies at presentation as indicators of severe dengue - Bernal, Cynthia; Ping, Sara; Rojas, Alejandra; Caballero, Oliver; Stittleburg, Victoria; de Guillén, Yvalena; Langjahr, Patricia; Pinsky, Benjamin A.; Von-Horoch, Marta; Luraschi, Patricia; Cabral, Sandra; Cecilia Sánchez, María; et al. (medRxiv, 2022)
Background Dengue is the most common vector-borne viral disease worldwide. Most cases are mild, but some evolve into severe dengue (SD), with high lethality. Therefore, it is important to identify biomarkers of severe disease to improve outcomes and judiciously utilize resources.Methods/Principal Findings One hundred forty-five confirmed dengue cases (median age, 42; range <1-91 years), enrolled from February 2018 to March 2020, were selected from an ongoing study of suspected arboviral infections in the Asunción metropolitan area. Cases included dengue virus types 1, 2, and 4, and severity was categorized according to the 2009 World Health Organization guidelines. Serologic and biomarker (lipopolysaccharide binding protein and chymase) testing were performed on acute-phase samples by ELISA; additional serologic testing was performed with the multiplex pGOLD assay. Complete blood counts and chemistries were performed at the discretion of the care team. Age, gender, and pre-existing comorbidities were associated with SD vs. dengue with/without warning signs in logistic regression with odds ratios (ORs) of 1.06 (per year; 95% confidence interval, 1.02, 1.10), 0.12 (female; 0.03,0.5), and 9.82 (presence; 1.92, 50.24) respectively. In binary logistic regression, for every unit increase in anti-DENV IgG in the pGOLD assay, odds of SD increased by 2.54 (1.19-5.42). Platelet count, lymphocyte percent, and elevated chymase were associated with SD in a combined logistic regression model with ORs of 0.99 (1,000/μL; 0.98,0.999), 0.92 (%; 0.86,0.98), and 1.17 (mg/mL; 1.03,1.33) respectively.Conclusions Multiple, readily available factors were associated with SD in this population. These findings will aid in the early detection of potentially severe dengue cases and inform the development of new prognostics for use in acute-phase and serial samples from dengue cases.Author Summary Dengue fever is an acute disease caused by dengue virus and transmitted to humans through the bite of infected Aedes mosquitoes. Dengue is the most common vector-borne viral disease worldwide affecting an estimated 50-100 million people and with 10,000 dengue-related deaths each year. Currently, there is no specific treatment, and safe and effective vaccines have not been fully implemented. Most dengue cases present with nonspecific mild symptoms, but some will evolve into severe dengue, which can be fatal. Early detection and subsequent timely treatment have been shown to decrease mortality among severe cases. Therefore, it is very important to identify biomarkers for the early identification of cases at risk for progression to severe disease. In this study we analyze demographic factors, clinical laboratory data, lipopolysaccharide binding protein and chymase to evaluate associations with disease severity. This study was carried out in Paraguay, which is a hyperendemic country for dengue where the disease has been understudied. A number of factors were found to be associated with severe disease in this population, including patient age, male gender, presence of comorbid illnesses, low platelet count, low lymphocyte percentage, and elevated chymase level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch was supported by an award from the Doris Duke Charitable Foundation (Clinical Scientist Development Award 2019089, JJW) National Institutes of Health/NIAID (grant R21 AI146443, JJW) and by the Consejo Nacional de Ciencia y Tecnología (CONACYT, PINV18-1295, AR and POSG17-59, CB), Paraguay. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. https://www.ddcf.org/ https://www.nih.gov/ https://www.conacyt.gov.py/Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Scientific and Ethics Committee of the Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción (IICS-UNA, IRB00011984), and the Emory University Institutional Review Board (IRB00000569).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.